U.S. Markets closed

Sorrento Therapeutics, Inc. (SRNE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.25+0.17 (+2.10%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.08
Open8.10
Bid8.24 x 1400
Ask8.20 x 1100
Day's Range7.97 - 8.27
52 Week Range5.17 - 17.25
Volume8,320,636
Avg. Volume5,931,423
Market Cap2.417B
Beta (5Y Monthly)2.37
PE Ratio (TTM)N/A
EPS (TTM)-0.91
Earnings DateMay 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.67
  • Motley Fool

    3 COVID Stocks That Might Double Soon

    Read more to find out why we think Novavax (NASDAQ: NVAX), Sorrento Therapeutics (NASDAQ: SRNE), and InMode (NASDAQ: INMD) will close out 2021 with a bang. Taylor Carmichael (Novavax): Novavax stock has already doubled this year, running from $112 back in January to $233 this week. Right now, Moderna enjoys a $169 billion market cap, and BioNTech sports a $79 billion valuation.

  • GlobeNewswire

    Dr. Henry Ji, Sorrento Chairman and CEO, to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

    SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the H.C. Wainwright 23rd Global Investment Conference (www.hcwevents.com/annualconference). The conference is being held virtually on September 13-15, 2021. Dr. Henry Ji, Chairman and CEO of Sorrento, will provide corporate updates and highlights associated with Sorrento’s product pipeline in the strategic focus areas of th

  • GlobeNewswire

    Sorrento Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in ICU Patients

    First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil.Second site scheduled to start enrolling within one week, with multiple additional sites coming online within one month. SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today the start of enrollment in its Phase 2 efficacy study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced